{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T23:12:00Z","timestamp":1726009920530},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,5,13]],"date-time":"2007-05-13T00:00:00Z","timestamp":1179014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Aim<\/jats:bold> To demonstrate the pharmacodynamic comparability between oral 40\u2003mg pantoprazole delayed\u2010release granules and tablets.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> This was a multicentre, randomized, open\u2010label, 2\u2010period, 2\u2010sequence, 9\u2010week crossover study in patients aged 18\u201365\u2003years with gastro\u2010oesophageal reflux disease and documented erosive oesophagitis. The primary endpoint was a comparison of the inhibition of pentagastrin\u2010stimulated maximum acid output (MAO) at steady state after once daily dosing for 1\u2003week and 23\u2003h after the last dose of pantoprazole granules and tablets. Basal acid output was measured prior to MAO. Standard safety evaluations were performed. The one\u2010sided <jats:italic>t<\/jats:italic>\u2010test was used to test the null hypothesis that granules \u2013 1.2\u2003\u00d7\u2003tablet\u2003\u2265\u20030 against the alternative hypothesis that this difference was &lt;0 for both MAO and basal acid output values.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> Sixty patients completed the study. The mean MAO values were 7.11\u2003\u00b1\u20034.98 and 7.29\u2003\u00b1\u20034.77\u2003mmol\/h, while the mean basal acid output values were 0.74\u2003\u00b1\u20030.91 and 0.58\u2003\u00b1\u20030.63\u2003mmol\/h for the granules and tablets, respectively. The two formulations were shown statistically to be pharmacodynamically equivalent in suppressing MAO (<jats:italic>P<\/jats:italic>\u2003=\u20030.006), safe and well tolerated.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> Patients with gastro\u2010oesophageal reflux disease who are unable to swallow the tablet may safely be prescribed the pantoprazole sodium granules.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2007.03375.x","type":"journal-article","created":{"date-parts":[[2009,11,20]],"date-time":"2009-11-20T04:02:02Z","timestamp":1258689722000},"page":"249-256","source":"Crossref","is-referenced-by-count":7,"title":["Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro\u2010oesophageal reflux disease and a history of erosive oesophagitis"],"prefix":"10.1111","volume":"26","author":[{"given":"D.","family":"HOGAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"PRATHA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"RIFF","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"DUCKER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"SCHWARTZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"SOFFER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"RATH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. M.","family":"COMER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,5,13]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01097.x"},{"issue":"1","key":"e_1_2_8_3_2","first-page":"597","article-title":"Prospective study of the long\u2010term efficacy and safety of lansoprozole in patients with Zollinger\u2010Ellison syndrome","volume":"7","author":"Jensen RT","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91170-9"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1993.tb00140.x"},{"key":"e_1_2_8_6_2","first-page":"240","volume-title":"Endocrine Tumors of the Pancreas: Frontiers in Gastrointestinal Research","author":"Metz DC","year":"1995"},{"key":"e_1_2_8_7_2","first-page":"587","volume-title":"Sleisenger and Fordtran\u2019s Gastrointestinal and Liver Diseases","author":"Feldman M","year":"1998"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.10.1.34"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01430.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-3096-0"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01834.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000199298","article-title":"24\u2010hour intragastric pH: continuous monitoring or nasogastric aspiration?","volume":"33","author":"Reynolds JR","journal-title":"Digestion"},{"key":"e_1_2_8_13_2","first-page":"53","article-title":"Testing the acid\u2010binding capacity of Tisacid suspension and tablets by intragastric pH determination in patients with hyperacidity","volume":"135","author":"Hunyady B","year":"1994","journal-title":"Orv Hetil"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105072"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01942.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03375.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03375.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T23:31:50Z","timestamp":1697239910000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03375.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,13]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03375.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03375.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,13]]}}}